The global CNS biomarker market is projected to reach $9.5 billion in 2027, fueled by factors such as public-private partnerships, government support, technological advancements, and the growing elderly population. Biomarkers are essential for early diagnosis and risk stratification in neurology, particularly in demyelinating and neurodegenerative diseases. The report provides comprehensive analysis, forecasts, and market dynamics for CNS biomarkers, including product strategies and emerging competitors, while also discussing the impact of Covid-19 and highlighting leading and emerging companies in the market.

Growing CNS Biomarker Market